Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 14/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | RGS12 | O14924 | 1/20 | 0.45 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.45 |
| ▸ | PDE6D | O43924 | 1/20 | 0.45 |
| ▸ | PDE8A | O60658 | 1/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458642 | 0.81 | SLC29A1 (0.46) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL141542 | 0.73 | SLC29A1 (0.61) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2456662 | 0.71 | SLC29A1 (0.38) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2457088 | 0.69 | GLP1R (0.43) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15065644 | 0.68 | SLC29A1 (0.55) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9565600 | 0.68 | SLC29A1 (0.53) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7446848 | 0.68 | SLC29A1 (0.53) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2456479 | 0.67 | SLC29A1 (0.43) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2458640 | 0.65 | SLC29A1 (0.41) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2459706 | 0.65 | SLC29A1 (0.41) | SLC29A1MEN1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011146819-A2 | METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES | DMD THERAPIES, LLC (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | WHALEN ANNE | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224128-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY | PYGM, TNNC1, MYOF | SLC29A1 3650/4885MEN1 4550/4885CYP3A4 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.